NewsBenzingaCorbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026 Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026 Benzinga 2026.10.22 12:03 (GMT+0) Open on Benzinga Other news Earnings Preview: What To Expect From Invitation Homes' Report Spotify’s current AI bet is about being the music service that agents choose INTC Stock Alert: What to Know as Intel Hits Construction Milestone at Ohio Fab Dear American Express Stock Fans, Mark Your Calendars for October 23 TD Cowen Maintains Buy on Kinder Morgan, Raises Price Target to $40 FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study
